By Professor David Goldstein

Journal articles

Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028

Tempero M; Cardin D; Biankin A; Goldstein D; Moore M; O’Reilly E; Philip P; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)', American Journal of Gastroenterology, 109, pp. S72 - S72, http://dx.doi.org/10.14309/00000434-201410002-00232

Tempero MA; Cardin D; Biankin A; Goldstein D; Moore M; O'Reilly EM; Philip PA; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'Apact: a Phase III Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Resected Pancreatic Cancer (Pc)', Annals of Oncology, 25, pp. iv252 - iv252, http://dx.doi.org/10.1093/annonc/mdu334.131

Huguet F; Hammel P; Vernerey D; Van Laethem J; Goldstein D; Glimelius B; Bonnetain F; Louvet C, 2014, 'Impact de la chimioradiothérapie sur le contrôle local et le temps sans traitement dans l’essai de phase III LAP07', Cancer/Radiothérapie, 18, pp. 587 - 587, http://dx.doi.org/10.1016/j.canrad.2014.07.013

Hammel P; Huguet F; Dewi V; Laethem J-LV; Goldstein D; Glimelius B; Artru P; Borbath Y; Bonnetain F; Louvet C, 2014, 'Impact of chemoradiotherapy (CRT) on local tumour control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study', Pancreatology, 14, pp. S6 - S6, http://dx.doi.org/10.1016/j.pan.2014.05.398

McCarroll J; Teo J; Boyer C; Goldstein D; Kavallaris M; Phillips PA, 2014, 'Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer', Frontiers in Physiology, 5, pp. 1 - 10, http://dx.doi.org/10.3389/fphys.2014.00002

Siena S; Lipton L; Letourneau R; Tjulandin SA; Guillen Ponce C; Schwarz M; Ramanathan RK; Macarulla T; Goldstein D; Romano A; Ferrara S; Penenberg D; Von Hoff DD, 2014, 'Regional Subanalysis of the Phase III Mpact Trial: Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients (Pts) with Metastatic Pancreatic Cancer (Pc)', Annals of Oncology, 25, pp. iv235 - iv235, http://dx.doi.org/10.1093/annonc/mdu334.76

Bell ML; Butow PN; Goldstein D, 2013, 'Informatively missing quality of life and unmet needs sex data for immigrant and Anglo-Australian cancer patients and survivors', Quality of Life Research, 22, pp. 2757 - 2760, http://dx.doi.org/10.1007/s11136-013-0392-y

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, http://dx.doi.org/10.1002/caac.21204

Kashigar A; Habbous S; Eng L; Irish B; Bissada E; Irish J; Brown D; Gilbert R; Gullane P; Xu W; Huang SH; Witterick I; Freeman J; O'Sullivan B; Waldron J; Liu G; Goldstein D, 2013, 'Erratum: Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. (Cancer (2013) 119 (27019))', Cancer, 119, pp. 3895 - 3896, http://dx.doi.org/10.1002/cncr.28281

Ackland S; Goldstein D; McJannett M, 2013, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37, pp. 238 - 242

Tan K; Goldstein D; Crowe P; Yang JL, 2013, 'Uncovering a key to the process of metastasis in human cancers: A review of critical regulators of anoikis', Journal of Cancer Research and Clinical Oncology, 139, pp. 1795 - 1805, http://dx.doi.org/10.1007/s00432-013-1482-5

Huguet F; Racadot S; Goldstein D; Spry N; Van Laethem J; Van Houtte P; Glimelius B; Gubanski M; Bonnetain F; Hammel P, 2013, 'Investigation of Relation of Radiation Therapy Quality Assurance Scores (RTQASc) With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma (LAPC)', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, pp. S29 - S30, http://dx.doi.org/10.1016/j.ijrobp.2013.06.080

Kiely BE; Martin AJ; Tattersall MHN; Nowak AK; Goldstein D; Wilcken NRC; Wyld DK; Abdi EA; Glasgow A; Beale PJ; Jefford M; Glare PA; Stockler MR, 2013, 'The median informs the message: Accuracy of individualized scenarios for survival time based on oncologists' estimates', Journal of Clinical Oncology, 31, pp. 3565 - 3571, http://dx.doi.org/10.1200/JCO.2012.44.7821

Grimison P; Phillips F; Butow P; White K; Yip D; Sardelic F; Underhill C; Tse R; Simes R; Turley K; Raymond C; Goldstein D, 2013, 'Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals', Asia-Pacific Journal of Clinical Oncology, 9, pp. 226 - 238, http://dx.doi.org/10.1111/ajco.12014

Chou A; Waddell N; Cowley MJ; Gill AJ; Chang DK; Patch AM; Nones K; Wu J; Pinese M; Johns AL; Miller DK; Kassahn KS; Nagrial AM; Wasan H; Goldstein D; Toon CW; Chin V; Chantrill L; Humphris J; Mead RS; Rooman I; Samra JS; Pajic M; Musgrove EA; Pearson JV; Morey AL; Grimmond SM; Biankin AV, 2013, 'Clinical and molecular characterization of HER2 amplified-pancreatic cancer', Genome Medicine, 5, pp. 78, http://dx.doi.org/10.1186/gm482

Shaw J; Butow P; Sze M; Young J; Goldstein D, 2013, 'Reducing disparity in outcomes for immigrants with cancer: A qualitative assessment of the feasibility and acceptability of a culturally targeted telephone-based supportive care intervention', Supportive Care in Cancer, 21, pp. 2297 - 2301, http://dx.doi.org/10.1007/s00520-013-1786-7

Butow PN; Sze M; Eisenbruch M; Bell ML; Aldridge LJ; Abdo S; Tanious M; Dong S; Iedema R; Vardy J; Hui R; Boyle F; Liauw W; Goldstein D, 2013, 'Should culture affect practice? A comparison of prognostic discussions in consultations with immigrant versus native-born cancer patients', Patient Education and Counseling, 92, pp. 246 - 252, http://dx.doi.org/10.1016/j.pec.2013.03.006

Huguet F; Van Laethem J-L; Goldstein D; Glimelius B; Artru P; Borbath I; Bouche O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2013, 'Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.', J Clin Oncol, 31, pp. LBA4003, http://dx.doi.org/10.1200/jco.2013.31.18_suppl.lba4003

Teo J; Erlich RB; Sagnella S; Dwarte T; Davis TP; Kavallaris M; McCarroll J; Boyer C; Duong HTT; Phillips P; Sharbeen G; Goldstein D, 2013, 'Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers', Molecular Pharmaceutics, 10, pp. 2435 - 2444, http://dx.doi.org/10.1021/mp400049e

Chiorean EG; Von Hoff DD; Ervin TJ; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; Ko A; Lu B, 2013, 'CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 31, pp. 4058 - 4058, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4058

Hammel P; Huguet F; Van Laethem J-L; Goldstein D; Glimelius B; Artru P; Borbath I; Bouche O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2013, 'Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.', Journal of Clinical Oncology, 31, pp. LBA4003 - LBA4003, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.lba4003

Pavlakis N; Goldstein D; Sjoquist KM; Martin A; Tsobanis E; Yip S; Shannon J; Burge ME; Cronk MF; Tebbutt NC; Strickland A; Lipton LR; Price TJ; Nott LM; Harris DL; Burnell MJ; Alcindor T; Bang Y-J; Kang Y-K; O'Callaghan CJ, 2013, 'INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).', Journal of Clinical Oncology, 31, pp. TPS4157 - TPS4157, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps4157

Moore MJ; Von Hoff DD; Ervin TJ; Arena FP; Chiorean EG; Infante JR; Hon JK; Biakhov MY; Hingorani SR; Ganju V; Weekes CD; Scheithauer W; Ramanathan RK; Tabernero J; Goldstein D; Wei X; Romano A, 2013, 'Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 31, pp. 4059 - 4059, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4059

Von Hoff DD; Ervin TJ; Arena FP; Chiorean EG; Infante JR; Moore MJ; Seay TE; Tjulandin S; Ma WW; Saleh MN; Harris M; Reni M; Ramanathan RK; Tabernero J; Hidalgo M; Van Cutsem E; Goldstein D; Wei X; Iglesias JL; Renschler MF, 2013, 'Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.', Journal of Clinical Oncology, 31, pp. 4005 - 4005, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4005

Butow PN; Sze M; Eisenbruch M; Bell M; Aldridge L; Vardy JL; Hui R; Boyle F; Liauw WS; Goldstein D, 2013, 'Should culture affect practice? Prognostic discussions with immigrants.', Journal of Clinical Oncology, 31, pp. 6556 - 6556, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6556

Vickers MM; Tu D; Lee C; Wheatley-Price P; Parulekar W; Brundage MD; Moore MJ; Au H-J; O'Callaghan CJ; Jonker DJ; Ringash J; Goldstein D, 2013, 'Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.', Journal of Clinical Oncology, 31, pp. 4053 - 4053, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4053

Webber K; Girgis A; Bennett BK; Bonaventura A; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602

Von Hoff DD; Ervin TJ; Arena FP; Chiorean EG; Infante JR; Moore MJ; Seay TE; Tjulandin S; Ma WW; Saleh MN; Harris M; Reni M; Ramanathan RK; Tabernero J; Hidalgo M; Van Cutsem E; Goldstein D; Wei X; Iglesias JL; Renschler MF, 2013, 'Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)', JOURNAL OF CLINICAL ONCOLOGY, 31, http://dx.doi.org/10.1200/jco.2013.31.4_suppl.lba148

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'S3I-201, a novel STAT3 inhibitor, inhibits growth of human soft tissue sarcoma cell lines', World Journal of Cancer Research, http://dx.doi.org/10.1166/wjcr.2013.1005

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204

Short M; Goldstein D; Halkett G; Reece W; Borg M; Zissiadis Y; Kneebone A; Spry N, 2013, 'Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer', International Journal of Radiation Oncology Biology Physics, 85, pp. 157 - 162, http://dx.doi.org/10.1016/j.ijrobp.2012.03.003

Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF, 2013, 'Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine', New England Journal of Medicine, 369, pp. 1691 - 1703, http://dx.doi.org/10.1056/NEJMoa1304369

Tan CJ; Yang JL; Crowe P; Goldstein D, 2013, 'Targeted therapy in soft tissue sarcoma-A novel direction in therapeutics', Chinese Clinical Oncology, 2, http://dx.doi.org/10.3978/j.issn.2304-3865.2013.08.01

Reni M; Von Hoff D; Chiorean E; Ervin T; Arena F; Infante J; Bathini V; Clingan P; Kunzmann V; Ramanathan R; Tabernero J; Goldstein D; Ko A; Lu B, 2013, 'CA19-9 Decrease and Kinetics in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer', Annals of Oncology, 24, pp. iv31 - iv31, http://dx.doi.org/10.1093/annonc/mdt202.19

Hammel P; Huguet F; van Laethem J-L; Goldstein D; Glimelius B; Borbath I; Bouché O; Shannon J; André T; Bonnetain F; Louvet C, 2013, 'Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study', Pancreatology, 13, pp. S89 - S89, http://dx.doi.org/10.1016/j.pan.2013.04.312

Huguet F; Hammel P; Goldstein D; Spry N; Van Laethem J-L; Van Houtte P; Glimelius B; Gubanski M; Bonnetain F; Racadot S, 2013, 'Étude de la relation entre le score d’assurance qualité de la radiothérapie, la toxicité et la survie dans l’essai de phase III LAP07 dans le cancer du pancréas localement évolué', Cancer/Radiothérapie, 17, pp. 581 - 582, http://dx.doi.org/10.1016/j.canrad.2013.06.018

Butow PN; Aldridge L; Bell M; Sze M; Eisenbruch M; Jefford M; Schofield P; Girgis A; King M; Duggal-beri P; Goldstein D, 2013, 'Inferior health-related quality of life and psychological well-being in immigrant cancer survivors: A population-based study', European Journal of Cancer, 49, pp. 1948 - 1956, http://dx.doi.org/10.1016/j.ejca.2013.01.011

Tabernero J; Von Hoff D; Moore M; Ervin T; Arena F; Chiorean E; Infante J; Hingorani S; Ganju V; Weekes C; Scheithauer W; Ramanathan R; Goldstein D; Wei X; Romano A, 2013, 'Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors on Survival', Annals of Oncology, 24, pp. iv11 - iv12, http://dx.doi.org/10.1093/annonc/mdt201.1

Butow PN; Bell M; Aldridge L; Sze M; Eisenbruch M; Jefford M; Schofield P; Girgis A; King M; Duggal-beri P; McGrane J; Goldstein D, 2013, 'Unmet needs in immigrant cancer survivors: a cross-sectional population-based study', Supportive Care in Cancer, 21, pp. 2509 - 2520, http://dx.doi.org/10.1007/s00520-013-1819-2

Goldstein D; Bennett BK; Webber K; Lloyd AR, 2012, 'Reply to A. Giacalone et al', Journal of Clinical Oncology, 30, pp. 4175 - 4176, http://dx.doi.org/10.1200/JCO.2012.45.6269

Ngan S; Fisher R; Burmeister B; Mackay J; McLachlan S; Beresford J; McClure B; Goldstein D; Joseph D; Solomon M, 2012, 'Long-term Quality of Life in Patients Treated in TROG 01.04: A Randomized Trial Comparing Short Course and Long Course Preoperative Radiation Therapy for Rectal Cancer', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84, pp. S143 - S144, http://dx.doi.org/10.1016/j.ijrobp.2012.07.371

Butow P; Aldridge L; Bell M; Sze M; Eisenbruch M; Jefford M; Schofield P; Girgis A; Goldstein D; King MT, 2012, 'Inferior quality of life and psychological well-being in immigrant cancer survivors', QUALITY OF LIFE RESEARCH, 21, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209358900132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fawcett J; Sjoquist KM; Padbury R; Christophi C; Tebbutt NC; Pilgrim CHC; Gebski V; Wong N; Aiken C; Goldstein D, 2012, 'ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.', Journal of Clinical Oncology, 30, pp. TPS3643 - TPS3643, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps3643

Butow PN; Aldridge L; Bell M; Sze M; Eisenbruch M; King M; Jefford M; Schofield P; Duggal-Beri P; Goldstein D, 2012, 'Cancer survivorship outcomes in immigrants.', Journal of Clinical Oncology, 30, pp. 6111 - 6111, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6111

Goldstein D; Sze M; Bell M; King M; Jefford M; Eisenbruch M; Girgis A; Vaccaro L; Butow PN, 2012, 'Disparities in quality-of-life outcomes in immigrant cancer patients.', Journal of Clinical Oncology, 30, pp. e16507 - e16507, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e16507

Chua YJ; Karapetis CS; Underhill C; Nott LM; Goldstein D; Cronk MF; Gebski V; Wong N; Sjoquist KM; Biankin AV, 2012, 'PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.', Journal of Clinical Oncology, 30, pp. TPS4137 - TPS4137, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4137

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044

Kiely BE; Martin AJ; Tattersall MHN; Nowak AK; Goldstein D; Wilcken N; Wyld D; Beale PJ; Jefford M; Glasgow AL; Abdi EA; Glare PA; Stockler MR, 2012, 'Usefulness of medical oncologists’ estimates of survival time in people with advanced cancer.', Journal of Clinical Oncology, 30, pp. 9087 - 9087, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9087

Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I; Romedi M; Ferrandini S; Rondinon M; Pittman K; Goldstein D; Shapiro J; Troon S; Yip D; Mainwaring P; Zigeuner R; Loidl W; Greil RF; Schmidinger M; De Grève J; Rottey S; Vermorken J; Gil T; Gennigens C; Roumeguere T; Barrios C; Mathias C; Assi H; Hotte S; Karakiewicz P; Knox J; Spadafora S; Wood L; Zalewski P; Mackensie M; Bjarnason G; Lalancette A; Chan A; Higgins B; North S; Soulieres D; Asselah J; Sperlich C; Miller W; Yadav S; El-Maraghi R; Godoy J; Prausová J; Katolicka J; Petruzelka L; Kiss I; Lapela M; Miller K; Bergmann L; Beck J; Jäger E; Kindler M; Overkamp F; Wirth M; Hölzer W; Gschwend J; Stenzl A; Gauler T; Niederwieser D; Marschner N; Lück A; Tessen H; Eichelberg C; Steiner T; Goebell P; Kettner E; Bakhshandeh-Bath A; Wilhelm M; Schmitz S; Jacob A; Bierer S; Kube U; Staehler M; Engel E; Frambach M; Schellenberger U; Albers P; Simon J; Gleissler M; Klotz T; Repp R, 2012, 'An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy', European Journal of Cancer, 48, pp. 324 - 332, http://dx.doi.org/10.1016/j.ejca.2011.06.054

Back to profile page